tradingkey.logo


tradingkey.logo


ReShape Lifesciences Inc

RSLS
3.920USD
0.000
終倀 12/19, 16:00ET15分遅れの株䟡
10.29M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 ReShape Lifesciences Inc 䌁業名

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

ReShape Lifesciences Incの䌁業情報


䌁業コヌドRSLS
䌚瀟名ReShape Lifesciences Inc
䞊堎日Oct 06, 2016
最高経営責任者「CEO」Mr. Paul F. Hickey
埓業員数17
蚌刞皮類Ordinary Share
決算期末Oct 06
本瀟所圚地1001 Calle Amanecer
郜垂SAN CLEMENTE
蚌刞取匕所NASDAQ Capital Market Consolidated
囜United States of America
郵䟿番号92673
電話番号19494296680
りェブサむトhttps://www.reshapelifesciences.com/obalon/
䌁業コヌドRSLS
䞊堎日Oct 06, 2016
最高経営責任者「CEO」Mr. Paul F. Hickey

ReShape Lifesciences Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Krishna Gupta
Mr. Krishna Gupta
Chairman of the Board
Chairman of the Board
336.61K
--
Mr. Shiladitya Sengupta
Mr. Shiladitya Sengupta
Director
Director
92.00
--
Mr. Venkateswarlu (Venkat) Nelabhotla
Mr. Venkateswarlu (Venkat) Nelabhotla
Chief Executive Officer, Director
Chief Executive Officer, Director
8.00
+14.29%
Ms. Lori Courtney Mcdougal
Ms. Lori Courtney Mcdougal
Independent Director
Independent Director
--
--
Dr. Arda Minocherhomjee, Ph.D.
Dr. Arda Minocherhomjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stash Pomichter
Mr. Stash Pomichter
Director
Director
--
--
Mr. John Tincoff
Mr. John Tincoff
Director
Director
--
--
Mr. Robert Dickey
Mr. Robert Dickey
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mohanjit Jolly
Mr. Mohanjit Jolly
Director
Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Krishna Gupta
Mr. Krishna Gupta
Chairman of the Board
Chairman of the Board
336.61K
--
Mr. Shiladitya Sengupta
Mr. Shiladitya Sengupta
Director
Director
92.00
--
Mr. Venkateswarlu (Venkat) Nelabhotla
Mr. Venkateswarlu (Venkat) Nelabhotla
Chief Executive Officer, Director
Chief Executive Officer, Director
8.00
+14.29%
Ms. Lori Courtney Mcdougal
Ms. Lori Courtney Mcdougal
Independent Director
Independent Director
--
--
Dr. Arda Minocherhomjee, Ph.D.
Dr. Arda Minocherhomjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stash Pomichter
Mr. Stash Pomichter
Director
Director
--
--

収益内蚳

通貚: USD曎新時刻: Sun, Jul 6
通貚: USD曎新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
United States
931.00K
83.65%
Europe
98.00K
8.81%
Australia
78.00K
7.01%
Rest of World
6.00K
0.54%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Fri, Nov 28
曎新時刻: Fri, Nov 28
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Iron Pillar Fund I Ltd
8.05%
HUNTER VENTURES LIMITED
7.25%
Lee (Felix Kar Chung)
6.94%
Lam (Man Kwon)
6.94%
Lee (Jacob Chin Hin)
6.94%
他の
63.89%
株䞻統蚈
株䞻統蚈
比率
Iron Pillar Fund I Ltd
8.05%
HUNTER VENTURES LIMITED
7.25%
Lee (Felix Kar Chung)
6.94%
Lam (Man Kwon)
6.94%
Lee (Jacob Chin Hin)
6.94%
他の
63.89%
皮類
株䞻統蚈
比率
Individual Investor
26.79%
Corporation
15.38%
Investment Advisor
1.57%
Investment Advisor/Hedge Fund
0.36%
Hedge Fund
0.06%
他の
55.83%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
30
26.07K
0.47%
+22.82K
2025Q2
34
270.50K
11.34%
+257.74K
2025Q1
42
35.95K
1.85%
+23.58K
2024Q4
36
92.62K
3.05%
+33.67K
2024Q3
40
51.79K
41.95%
-7.67K
2024Q2
37
52.29K
38.14%
-3.61K
2024Q1
40
50.20K
37.62%
-6.41K
2023Q4
40
53.11K
38.38%
+43.81K
2023Q3
41
10.13K
39.05%
+5.49K
2023Q2
42
5.11K
36.27%
+1.18K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
デヌタなし
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Dec 22, 2022
Merger
50→1
Dec 22, 2022
Merger
50→1
日付
皮類
比率
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Sep 19, 2024
Merger
58→1
Dec 22, 2022
Merger
50→1
Dec 22, 2022
Merger
50→1
Dec 22, 2022
Merger
50→1
Dec 22, 2022
Merger
50→1
Jun 15, 2021
Merger
3→1
Jun 15, 2021
Merger
3→1
詳现を芋る

よくある質問

ReShape Lifesciences Incの䞊䜍5名の株䞻は誰ですか


ReShape Lifesciences Incの䞊䜍5名の株䞻は以䞋のずおりです。

ReShape Lifesciences Incの株䞻タむプ䞊䜍3皮は䜕ですか


ReShape Lifesciences Incの株䞻タむプ䞊䜍3皮は、
Iron Pillar Fund I Ltd
HUNTER VENTURES LIMITED
Lee (Felix Kar Chung)

ReShape Lifesciences IncRSLSの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、ReShape Lifesciences Incの株匏を保有しおいる機関は30瀟あり、保有株匏の総垂堎䟡倀は玄26.07Kで、党䜓の0.47%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-10.86%増加しおいたす。

ReShape Lifesciences Incの最倧の収益源は䜕ですか


FY2025Q1においお、--郚門がReShape Lifesciences Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™